Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Inhibiting MAPK14 showed anti-prolactinoma effect

Fig. 2

Effects of MAPK14 knockout on the development of prolactinoma in ES-induced mice. a Plasma PRL levels in the WT mice, ES-injected mice and ES-injected MAPK14−/− mice. **P < 0.01 vs. WT; ##P < 0.01 vs. E2, (n = 3). b Relative PRL mRNA expression levels in the pituitary gland of mice. **P < 0.01 vs. WT; ##P < 0.01 vs. ES, (n = 3). c Pituitary gland weight/body weight ratio. ***P < 0.001 vs. WT; ###P < 0.001 vs. ES, (n = 6). d PRL protein expression levels in the pituitary gland of mice. e Relative PRL protein expression levels were quantified and normalized to β-actin. **P < 0.01 vs. WT; #P < 0.05 vs. ES, (n = 3)

Back to article page